Revvity Inc
RVTY
View Detailed Chart
84.000USD
+1.130+1.36%
Close 09/15, 16:00（ET）Quotes delayed by 15 min
9.77BMarket Cap
34.26P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.36%
5 Days
-2.64%
1 Month
-7.47%
6 Months
-24.94%
Year to Date
-24.74%
1 Year
-31.16%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-15Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
20
analysts
Buy
Current Rating
120.359
Target Price
+45.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 12.14%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 12.14%.
Fairly Valued
The company’s latest PE is 35.70, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 113.79M shares, decreasing 5.83% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 14.03M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.
Ticker SymbolRVTY
CompanyRevvity Inc
CEODr. Prahlad R. Singh, Ph.D.
Websitehttps://www.revvity.com/
Related Instruments
-1.04%
-3.49%
-2.77%
-0.79%
-0.06%
-1.96%
+0.39%
+1.94%
+1.73%
-0.11%
+1.24%
+6.10%
-1.01%
-2.04%
+3.75%
-0.24%
-1.13%
+0.09%
+1.23%
+1.35%
